Blog
RSS FeedPosted by Michael Wonder on 21 Jan 2018
At $262.40 per pill, the cancer drug that could save her life isn’t covered in B.C.
19 January 2018 - Karen McLaren of Langley has stage four breast cancer, and has been prescribed a drug that could ...
Posted by Michael Wonder on 25 Sep 2017
First-in-class BRCA-positive ovarian cancer medicine Lynparza (olaparib) receives positive pan-Canadian Oncology Drug Review recommendation for provincial reimbursement
21 September 2017 - This marks an important first step towards providing Canadian women with access to this treatment. ...
Posted by Michael Wonder on 05 Sep 2017
CADTH recommends olaparib following supply of results from phase 3 trial
5 September 2017 - CADTH has published its initial recommendation for olaparib for use as monotherapy maintenance treatment of adult patients ...
Posted by Michael Wonder on 05 Sep 2017
CADTH publishes final outcome for Opdivo for head and neck cancer
5 September 2017 - CADTH has completed its assessment of nivolumab for the treatment of adults with recurrent or metastatic ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for daratumumab
3 August 2017 - CADTH has published its initial recommendation on the use of daratumumab for use in combination with ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for Keytruda
3 August 2017 - CADTH has published its initial recommendation on the use of pembrolizumab for use by untreated patients ...
Posted by Michael Wonder on 29 Jul 2017
‘It’s very frustrating’: ovarian cancer patient waiting on potential approval of new treatment
27 July 2017 - Seventy-five women are diagnosed with ovarian cancer in Saskatchewan each year, and fifty-five lose their lives. ...
Posted by Michael Wonder on 06 Jul 2017
Canadians living with multiple myeloma need access to therapies now
4 July 2017 - Multiple myeloma, commonly referred to as myeloma, is an incurable cancer of the plasma cells found in ...
Posted by Michael Wonder on 09 Jun 2017
Public funding of approved lung cancer treatments needed now
7 June 2017 - The Canadian Cancer Survivor Network and Lung Cancer Canada are calling on government and industry to ...
Posted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...
Posted by Michael Wonder on 09 May 2017
Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer
8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get ...
Posted by Michael Wonder on 05 May 2017
Engaging specialist oncologists in the assessment of oncology drugs in Canada
1 May 2017 - The assessment of new cancer drugs in Canada increasingly engages specialist oncology physicians. This has not always ...
Posted by Michael Wonder on 27 Apr 2017
Cancer care drug costs concern group
26 April 2017 - Jennifer McGrady has never even touched a cigarette. ...
Posted by Michael Wonder on 31 Mar 2017
pERC publishes initial recommendation for Roche's Gazyva
30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final recommendation for Sanofi Genzyme's Caprelsa
30 March 2017 - The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary ...